Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
Status:
Terminated
Trial end date:
2016-01-22
Target enrollment:
Participant gender:
Summary
This study is looking at the efficacy, rapidity, safety, and tolerability of two doses of
oral CERC-501 for treating patients with treatment resistant depression who are taking an
antidepressant that is not working for them.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Butler Hospital National Institute of Mental Health (NIMH) Rush University Temple University University of Kansas University of Kansas Medical Center